New combo shows promise against rare sarcoma
NCT ID NCT04807816
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tested whether adding the drug berzosertib to standard chemotherapy (gemcitabine) can help control a rare type of soft-tissue cancer called leiomyosarcoma. Fifty-eight adults with advanced disease that had worsened despite prior treatments took part. The main goal was to see how many patients had their tumors shrink or stay stable for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Poitiers
Poitiers, 86000, France
-
Centre Leon Berard
Lyon, 69008, France
-
IUCT Oncopôle
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.